Well differentiated thyroid cancer

Scandinavian Journal of Surgery

Volumn 93, Issue 4, 2004, Pages 261-271

  Caron, N R ^a   Clark, Orlo H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Follicular thyroid cancer; Hurthle cell thyroid cancer; Papillary thyroid cancer; Well differentiated thyroid cancer

Indexed keywords

FOLLITROPIN; HISTONE DEACETYLASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RADIOACTIVE IODINE; SODIUM IODIDE SYMPORTER; THYROGLOBULIN; THYROTROPIN; TRICHOSTATIN A;

CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SCREENING; CELL DIFFERENTIATION; HISTOPATHOLOGY; HORMONAL REGULATION; HUMAN; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RECURRENT DISEASE; REVIEW; SCINTIGRAPHY; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROID PARAFOLLICULAR CELL; TUMOR RECURRENCE;

EID: 11844251127     PISSN: 14574969     EISSN: None     Source Type: Journal    
DOI: 10.1177/145749690409300403     Document Type: Review

References (24)

1. Kebebew E, Clark OH: Differentiated thyroid cancer: "complete" rational approach. World J Surg 2000;24:942-951
2. Ringel MD, Ladenson PW: Controversies in the follow-up and management of well-differentiated thyroid cancer. Endocr Relat Cancer 2004;11:97-116
3. Busnardo B, De Vido D: The epidemiology and etiology of differentiated thyroid carcinoma. Biomed Pharmacother 2000;54:322-326
4. Gow KW, Lensing S, Hill DA, Krasin MJ, McCarville MB, Rai SN, Zacher M, Spunt SL, Strickland DK, Hudson MM: Thyroid carcinoma presenting in childhood or after treatment of childhood malignancies: An institutional experience and review of the literature. J Pediatr Surg 2003;38:1574-1580
5. Hellman P, Goretzki P, Witte J, Roeher H: Follicular thyroid cancer. In: Surgical Endocrinology. Eds G.M. Doherty, B. Skogseid. Philadelphia, Lippincott Williams & Wilkins, 2001, pp. 75-86
6. D'Avanzo A, Treseler P, Ituarte PH, Wong M, Streja L, Greenspan FS, Siperstein AE, Duh QY, Clark OH: Follicular thyroid carcinoma: histology and prognosis. Cancer 2004;100:1123-1129
7. Segev DL, Umbricht C, Zeiger MA: Molecular pathogenesis of thyroid cancer. Surg Oncol 2003;12:69-90
8. Tallini G: Molecular pathobiology of thyroid neoplasms. Endocr Pathol 2002;13:271-288
9. Kebebew E, Clark OH: Papillary thyroid cancer. In: Surgical Endocrinology. Eds G.M. Doherty, B. Skogseid. Philadelphia, Lippincott Williams & Wilkins, 2001, pp. 59-74
10. Zidan J, Karen D, Stein M, Rosenblatt E, Basher W, Kuten A: Pure versus follicular variant of papillary thyroid carcinoma: clinical features, prognostic factors, treatment, and survival. Cancer 2003;97:1181-1185
11. Carcangiu ML, Zampi G, Rosai J: Papillary thyroid carcinoma: a study of its many morphologic expressions and clinical correlates. Pathol Annu 1985;20 Pt 1:1-44
12. LiVolsi VA: Pure versus follicular variant of papillary thyroid carcinoma: clinical features, prognostic factors, treatment, and survival. Cancer 2003;98:1997; author reply 1997-1998
13. Grossman RF, Clark OH: Hurthle cell carcinoma. Cancer Control 1997;4:13-17
14. Karam M, Gianoukakis A, Feustel PJ, Cheema A, Postal ES, Cooper JA: Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates. Nucl Med Commun 2003;24:489-495
15. Mazzaferri EL, Jhiang SM: Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418-428
16. Angelos P: Current approaches to the treatment of well-differentiated thyroid cancer. Oncology (Huntingt) 2002;16:309-315; discussion 315, 318, 323-304
17. McGriff NJ, Csako G, Gourgiotis L, Lori CG, Pucino F, Sarlis NJ: Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann Med 2002;34:554-564
18. Ford D, Giridharan S, McConkey C, Hartley A, Brammer C, Watkinson JC, Glaholm J: External beam radiotherapy in the management of differentiated thyroid cancer. Clin Oncol (R Coll Radiol) 2003;15:337-341
19. Zarnegar R, Brunaud L, Kanauchi H, Wong M, Fung M, Ginzinger D, Duh QY, Clark OH: Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using Trichostatin A, a histone deacetylase inhibitor. Surgery 2002;132:984-990; discussion 990
20. Park JW, Clark OH: Redifferentiation therapy for thyroid cancer. Surg Clin North Am 2004;84:921-943
21. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, Haugen BR, Sherman SI, Cooper DS, Braunstein GD, Lee S, Davies TF, Arafah BM, Ladenson PW, Pinchera A: A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003;88:1433-1441
22. Khan N, Oriuchi N, Higuchi T, Zhang H, Endo K: PET in the follow-up of differentiated thyroid cancer. Br J Radiol 2003;76:690-695
23. Lind P, Kresnik E, Kumnig G, Gallowitsch HJ, Igerc I, Matschnig S, Gomez I: 18F-FDG-PET in the follow-up of thyroid cancer. Acta Med Austriaca 2003;30:17-21
24. Chin BB, Patel P, Cohade C, Ewertz M, Wahl R, Ladenson P: Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. J Clin Endocrinol Metab 2004;89:91-95